Source: Arquivos Brasileiros de Cardiologia. Unidade: FMRP
Subjects: INFARTO DO MIOCÁRDIO, VASOS CORONÁRIOS, REPERFUSÃO, COMPLEXO GLICOPROTEICO GPIIA DE PLAQUETAS, ANGIOPLASTIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAGO, Igor Matos et al. In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention: a pilot randomized study. Arquivos Brasileiros de Cardiologia, v. 107, n. 5, p. 403-410, 2016Tradução . . Disponível em: https://doi.org/10.5935/abc.20160149. Acesso em: 16 nov. 2024.APA
Lago, I. M., Novaes, G. C., Badran, A. V., Pavão, R. B., Barbosa, R., Figueiredo, G. L. de, et al. (2016). In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention: a pilot randomized study. Arquivos Brasileiros de Cardiologia, 107( 5), 403-410. doi:10.5935/abc.20160149NLM
Lago IM, Novaes GC, Badran AV, Pavão RB, Barbosa R, Figueiredo GL de, Lima Filho M de O, Haddad JL, Schmidt A, Marin Neto JA. In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention: a pilot randomized study [Internet]. Arquivos Brasileiros de Cardiologia. 2016 ; 107( 5): 403-410.[citado 2024 nov. 16 ] Available from: https://doi.org/10.5935/abc.20160149Vancouver
Lago IM, Novaes GC, Badran AV, Pavão RB, Barbosa R, Figueiredo GL de, Lima Filho M de O, Haddad JL, Schmidt A, Marin Neto JA. In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention: a pilot randomized study [Internet]. Arquivos Brasileiros de Cardiologia. 2016 ; 107( 5): 403-410.[citado 2024 nov. 16 ] Available from: https://doi.org/10.5935/abc.20160149
